Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

TNF-based isolated hepatic perfusion.

Bellavance EC, Alexander HR Jr.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1771-84. Review.

PMID:
19273161
2.

The past decade of experience with isolated hepatic perfusion.

Grover A, Alexander HR Jr.

Oncologist. 2004;9(6):653-64. Review.

3.

Isolation perfusion of the liver.

Carroll NM, Alexander HR Jr.

Cancer J. 2002 Mar-Apr;8(2):181-93. Review.

PMID:
12004803
4.
5.

Transarterial perfusion of liver metastases.

Weinreich DM, Alexander HR.

Semin Oncol. 2002 Apr;29(2):136-44. Review.

PMID:
11951211
6.

Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.

Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E.

Clin Cancer Res. 1998 Oct;4(10):2357-62.

7.

Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.

van Ijken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont AM.

J Immunother. 2000 Jul-Aug;23(4):449-55.

PMID:
10916754
8.

Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.

Lindnér P, Fjälling M, Hafström L, Kierulff-Nielsen H, Mattsson J, Scherstén T, Rizell M, Naredi P.

Eur J Surg Oncol. 1999 Apr;25(2):179-85.

PMID:
10218462
9.
10.

A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.

Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC.

Clin Cancer Res. 2000 Aug;6(8):3062-70.

11.
12.

A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.

Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM, Bartlett DL.

Ann Surg Oncol. 2009 Feb;16(2):385-94. doi: 10.1245/s10434-008-0179-5.

PMID:
19034580
13.

A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.

Nakamoto T, Inagawa H, Takagi K, Soma G.

Anticancer Res. 2000 Nov-Dec;20(6A):4087-96. Review.

PMID:
11131677
14.

Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.

Lans TE, Bartlett DL, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR.

Clin Cancer Res. 2001 Apr;7(4):784-90.

15.

Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion.

Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR.

J Gastrointest Surg. 2004 Feb;8(2):200-7.

PMID:
15036196
16.

Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution.

Magge D, Choudry HA, Zeh HJ 3rd, Cunningham DE, Steel J, Holtzman MP, Jones HL, Pingpank JF, Bartlett DL, Zureikat AH.

Ann Surg. 2014 May;259(5):953-9. doi: 10.1097/SLA.0000000000000261.

PMID:
24169176
17.

Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.

Rothbarth J, Tollenaar RA, Schellens JH, Nortier JW, Kool LJ, Kuppen PJ, Mulder GJ, van de Velde CJ.

Eur J Cancer. 2004 Aug;40(12):1812-24. Review.

PMID:
15288282
18.

Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.

De Vries MR, Borel Rinkes IH, Swaak AJ, Hack CE, Van De Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Eggermont AM.

Eur J Clin Invest. 1999 Jun;29(6):553-60.

PMID:
10354218
19.

Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies.

Jones A, Alexander HR Jr.

Surg Oncol Clin N Am. 2008 Oct;17(4):857-76, x. doi: 10.1016/j.soc.2008.04.011. Review.

PMID:
18722923
20.

Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center.

Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH.

Ann Surg Oncol. 2009 Jul;16(7):1852-9. doi: 10.1245/s10434-009-0482-9.

PMID:
19434456

Supplemental Content

Support Center